Cullinan Therapeutics Inc (NAS:CGEM)

$ 22.84 0.44 (1.96%) Market Cap: 1.32 Bil Enterprise Value: 861.16 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 36/100

Cullinan Oncology Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Cullinan Oncology Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 26, 2023
Cullinan Oncology Inc To Discuss About Licensing Agreement with Harbour Biomed Transcript
Feb 14, 2023
Cullinan Oncology Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022
Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Taiho To Acquire Cullinan Oncology's Subsidiary, Cullinan Pearl - M&A Call Transcript
May 12, 2022
Cullinan Oncology Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 13, 2022
Cullinan Oncology Inc To Host CLN-081 Regulatory Update Webinar Transcript
Mar 28, 2022
Cullinan Oncology Inc at Barclays Global Healthcare Conference Transcript
Mar 16, 2022
Cullinan Oncology Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Cullinan Oncology Inc To Provide CLN-081 Clinical Update Webinar Call Transcript
Dec 16, 2021
Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
Cullinan Oncology Inc Pearl Clinical Update Call Transcript
Jun 04, 2021

Cullinan Oncology Inc To Discuss About Licensing Agreement with Harbour Biomed Transcript

Feb 14, 2023 / 01:00PM GMT

Release Date Price: $11.38 (+2.99%)

Transcript 8-K

Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the [Cullinan Oncology Harbour BioMed Licensing] Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker host today, Chad Messer, Vice President of Investor Relations. Please go ahead.

Chad Messer

Hello, everyone. And thank you all for joining us to discuss our license agreement with Harbour BioMed for exclusive U.S. development and commercial rights to CLN-418. My name is Chad Messer, and I'm the Vice President of Investor Relations at Cullinan Oncology. Joining me on today's call are Nadim Ahmed, Chief Executive Officer; Dr. Jeffrey Jones, our Chief Medical Officer; and Corinne Savill, our Chief Business Officer. Jeff Trigilio, Chief Financial Officer; and Dr. Patrick Baeuerle, our Chief Scientific Officer and Co-Founder, are also on the line and will be available during the Q&A session.

Before we begin, I would like to remind you of the safe harbor provisions

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.